Theriva Doses First Patient in VIRAGE2 Phase 2a Trial
Theriva Biologics announced the dosing of the first patient in the VIRAGE2 trial to evaluate more frequent dosing of VCN-01 in first-line metastatic pancreatic cancer, following positive data from its previous Phase 2b study.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day